Alzamend Neuro, Inc.: directors' dealings · United States · SEC (Form 4)

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc. (ticker: ALZN) is a U.S.-based clinical-stage biopharmaceutical company listed on Nasdaq in the United States. For French-speaking investors, it is a very small-cap healthcare name whose investment case is driven primarily by clinical execution, regulatory progress, and financing capacity rather than commercial sales. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia, with historical ties to Florida and ongoing collaboration with major U.S. research institutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm?utm_source=openai)) Alzamend’s strategy is narrowly focused on neurodegenerative and psychiatric disorders, especially Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its current pipeline is centered on two main programs. AL001 is a patented ionic cocrystal lithium formulation combining lithium, salicylate, and L-proline, designed to improve delivery of lithium to the brain while reducing systemic exposure compared with conventional lithium carbonate. ALZN002 is a cell-based therapeutic vaccine approach using a mutant-peptide-sensitized cell intended to help restore the patient’s immune response and remove beta-amyloid from the brain. Both candidates are licensed from the University of South Florida Research Foundation under royalty-bearing exclusive worldwide licenses. ([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/97/alzamend-neuro-announces-completion-of-clinical-portion-of?utm_source=openai)) From a competitive standpoint, Alzamend occupies a highly specialized and speculative niche in CNS drug development: next-generation lithium delivery and an Alzheimer’s immunotherapy concept. The company does not yet have a marketed product, so the investment thesis depends on clinical readouts, regulatory milestones, and its ability to fund development over time. That makes the story high-risk/high-reward, with material dilution and execution risk typical of early-stage biotech issuers. ([ir.alzamend.com](https://ir.alzamend.com/company-information?utm_source=openai)) Recent developments have been important for the stock narrative. In 2025 and 2026, Alzamend reported multiple Phase II updates for AL001, including initiation and completion of clinical work and, most notably, preliminary positive data showing bioequivalence and numerically superior brain delivery versus standard lithium carbonate across the measured brain regions. The company also announced that it had regained compliance with Nasdaq listing standards in October 2024. These milestones improve the clinical profile, but they do not remove the inherent binary risk associated with a development-stage biotech company. ([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its?utm_source=openai))